Novavax (NVAX) Cash from Operations (2010 - 2026)
Novavax (NVAX) posted quarterly Cash from Operations of 32400000.0 for Q1 2026, up 82.53% year-over-year from 17750129.35 in Q1 2025, and up 17.92% quarter-over-quarter from 39475000.0 in Q4 2025.
Novavax (NVAX) Cash from Operations (2010 - 2026) Analysis & Trends
Novavax's Cash from Operations history runs 17 years deep, the most recent figure standing at 32400000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 82.53% year-over-year to 32400000.0; the TTM figure through Mar 2026 stood at 91533000.0 (up 51.62% YoY), while the FY2025 annual figure was 244635000.0, down 180.34% from the prior year.
- Cash from Operations for Q1 2026 stood at 32400000.0, up from 39475000.0 in the prior quarter.
- The five-year high for Cash from Operations was 314269000.0 in Q2 2024, with the low at 325593000.0 in Q1 2023.
- The 5-year median for Cash from Operations is 117816000.0 (2022), against an average of 87894235.29.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations plunged 267.86% in 2023, then surged 282.78% in 2024.
- Novavax's Cash from Operations stood at 117816000.0 in 2022, then tumbled by 50.05% to 176781000.0 in 2023, then climbed by 2.05% to 173163000.0 in 2024, then surged by 77.2% to 39475000.0 in 2025, then increased by 17.92% to 32400000.0 in 2026.
- Business Quant data shows NVAX's Cash from Operations at 32400000.0 in Q1 2026, 39475000.0 in Q4 2025, and 107840000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn | -72.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -72.81 Mn |
| Jun 30, 2026 | -72.81 Mn |
| Mar 31, 2026 | -32.40 Mn |
| Mar 31, 2026 | -32.40 Mn |
| Dec 31, 2025 | -39.48 Mn |
| Dec 31, 2025 | -39.48 Mn |
| Sep 30, 2025 | 107.84 Mn |
| Sep 30, 2025 | 107.84 Mn |
| Jun 30, 2025 | -127.50 Mn |
| Jun 30, 2025 | -127.50 Mn |
| Mar 31, 2025 | -185.50 Mn |
| Mar 31, 2025 | -185.50 Mn |
| Dec 31, 2024 | -173.16 Mn |
| Dec 31, 2024 | -173.16 Mn |
| Sep 30, 2024 | -144.81 Mn |
| Sep 30, 2024 | -144.81 Mn |
| Jun 30, 2024 | 314.27 Mn |
| Jun 30, 2024 | 314.27 Mn |
| Mar 31, 2024 | -83.56 Mn |
| Mar 31, 2024 | -83.56 Mn |